Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 4/20 | 0.66 |
| ▸ | FBP1 | P09467 | 13/20 | 0.62 |
| ▸ | EGFR | P00533 | 2/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | ABL2 | P42684 | 1/20 | 0.53 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.52 |
| ▸ | MITF | O75030 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TERT | O14746 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807974 | 1.00 | VCP (0.66) | VCPFBP1EGFRABL1ABL2 | |
| SCHEMBL807786 | 0.86 | VCP (0.61) | VCPFBP1EGFRABL1ABL2 | |
| SCHEMBL793177 | 0.86 | VCP (0.61) | VCPFBP1EGFRABL1ABL2 | |
| SCHEMBL793784 | 0.84 | VCP (0.72) | VCPFBP1EGFRABL1ABL2 | |
| SCHEMBL4491460 | 0.84 | VCP (0.72) | VCPFBP1EGFRABL1ABL2 | |
| SCHEMBL798036 | 0.84 | FBP1 (0.63) | VCPFBP1EGFRABL1ABL2 | |
| SCHEMBL794027 | 0.84 | FBP1 (0.63) | VCPFBP1EGFRABL1ABL2 | |
| SCHEMBL30592059 | 0.84 | VCP (0.72) | VCPFBP1EGFRABL1ABL2 | |
| SCHEMBL13773077 | 0.79 | EGFR (0.72) | VCPFBP1EGFRABL1ABL2 | |
| SCHEMBL8010226 | 0.79 | EGFR (0.72) | VCPFBP1EGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946260-B2 | 17α-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| CN-103108871-A | 17a-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2013-05-15 | — | — | CN | disclosed |
| CN-101318961-B | Fused heterocyclic compound | JANSSEN PHARMACEUTICA NV | 2012-11-28 | — | — | CN | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-7897771-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-03-01 | — | — | US | disclosed |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-17 | — | — | US | disclosed |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-29 | — | — | US | disclosed |
| US-7579470-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | disclosed |
| US-7402680-B2 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-07-22 | — | — | US | disclosed |
| EP-1944306-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-07-16 | — | — | EP | disclosed |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-05-01 | — | — | US | disclosed |
| EP-1905774-A1 | Fused heterocyclic compounds as serotonin receptor modulators | Janssen Pharmaceutica, N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| CN-1882590-A | Fused heterocyclic compounds as serotonin receptor modulators | JOHNSON & JOHNSON (BE) | 2006-12-20 | — | — | CN | disclosed |
| EP-1668014-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-14 | — | — | EP | disclosed |
| US-20050119295-A1 | Fused heterocyclic compounds | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-02 | — | — | US | disclosed |
| WO-2005040169-A2 | FUSED HETEROCYCLIC COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119295-A1 | Fused heterocyclic compounds | TPH1, HTR3A, HTR3B | VCP 4173/4885FBP1 1093/4885EGFR 4700/4885 |
| US-20110040088-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | VCP 4173/4885FBP1 1093/4885EGFR 4700/4885 |
| US-20090270370-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | VCP 4173/4885FBP1 1093/4885EGFR 4700/4885 |
| US-20080103132-A1 | FUSED HETEROCYCLIC COMPOUNDS | TPH1, HTR3A, HTR3B | VCP 4173/4885FBP1 1093/4885EGFR 4700/4885 |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | VCP 3835/4885FBP1 2302/4885EGFR 2155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.